These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15195157)

  • 1. [Third-generation oral contraceptives--how big is the risk of venous thrombosis?].
    Iversen OE
    Tidsskr Nor Laegeforen; 2004 Jun; 124(11):1521-2. PubMed ID: 15195157
    [No Abstract]   [Full Text] [Related]  

  • 2. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 3. [Third generation oral contraceptives and risk of venous thrombosis].
    Olsen J
    Ugeskr Laeger; 2002 Jan; 164(3):346. PubMed ID: 11816336
    [No Abstract]   [Full Text] [Related]  

  • 4. Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis?
    Sapp AV; Lindbloom EJ
    J Fam Pract; 2001 Oct; 50(10):893. PubMed ID: 11674894
    [No Abstract]   [Full Text] [Related]  

  • 5. [Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations].
    Milsom I; Odlind V; von Schoultz B; Ostlund I; Persson E
    Lakartidningen; 2002 Jan; 99(1-2):10-2, 15. PubMed ID: 11871161
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of venous thromboembolism with third-generation oral contraceptives: A review.
    Weiss G
    Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 2):295-301. PubMed ID: 9988833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of oral contraceptives and cardiovascular disease.
    Vandenbroucke JP; Helmerhorst FM; Rosendaal FR
    Ann Intern Med; 1998 Nov; 129(9):747. PubMed ID: 9841612
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third generation oral contraceptives.
    Skegg DC
    BMJ; 2000 Jul; 321(7255):190-1. PubMed ID: 10903631
    [No Abstract]   [Full Text] [Related]  

  • 11. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
    BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone-based contraceptive therapy and risk of venous thromboembolism in young women.
    Roberts H
    Clin Adv Hematol Oncol; 2010 May; 8(5):307-9. PubMed ID: 20551888
    [No Abstract]   [Full Text] [Related]  

  • 13. Third generation oral contraceptives--the controversy.
    Carnall D; Karcher H; Lie LG; Sheldon T; Spurgeon D; Josefson D; Zinn C
    BMJ; 1995 Dec; 311(7020):1589-90. PubMed ID: 8555796
    [No Abstract]   [Full Text] [Related]  

  • 14. Third generation oral contraceptives containing desogestrel and gestodene and the risk of thrombosis.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1996 Mar; 15(1):5-7. PubMed ID: 8920631
    [No Abstract]   [Full Text] [Related]  

  • 15. [Third generation oral contraceptives and risk of venous thrombosis--the English lesson].
    Sørensen MB
    Ugeskr Laeger; 2002 Apr; 164(18):2418; author reply 2418-9. PubMed ID: 12024851
    [No Abstract]   [Full Text] [Related]  

  • 16. Scare over oral contraceptives. Studies implicate only gestodene and desogestrel.
    Donnelly RJ
    BMJ; 1995 Dec; 311(7020):1639. PubMed ID: 8555821
    [No Abstract]   [Full Text] [Related]  

  • 17. The differential risk of oral contraceptives: the impact of full exposure history.
    Lewis MA; MacRae KD; Kühl-Habichl D; Bruppacher R; Heinemann LA; Spitzer WO
    Hum Reprod; 1999 Jun; 14(6):1493-9. PubMed ID: 10359554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral venous thrombosis as a complication of oral contraceptive use in a 15-year-old patient: a case report.
    Hill LW; Hindelang FM
    J La State Med Soc; 2007; 159(4):195, 197. PubMed ID: 17987956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill.
    Black C; Kaye JA; Jick H
    Br J Clin Pharmacol; 2002 Jun; 53(6):637-40. PubMed ID: 12047488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancies and terminations after 1995 warning about third-generation oral contraceptives.
    Jick SS; Vasilakis C; Jick H
    Lancet; 1998 May; 351(9113):1404-5. PubMed ID: 9593415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.